The Scripps Research Institute

University of California

Medtronic Minimed, Inc.

Other

California Institute of Technology

Novartis Ag

Symyx Technologies, Inc.

Irm LLC

The University of Texas System

Chiron Corporation

Massachusetts Institute of Technology

The State University of New York

The Salk Institute for Biological Studies

U.S. Department of Energy

Symyx Solutions, Inc.

Peter G Schultz

Zhiwen Zhang

Lei Wang

Jason W Chin

J Christopher Anderson

Isy Goldwasser

David R Liu

Travis Young

John Christopher Anderson

Thomas J Magliery

Rajiv Shah

Udo Hoss

James L Henke

Xiaodong Xiang

Kai-An Wang

Hank Michael James Petrassi

Leonard G Presta

Nathanael Schiander Gray

Sheldon B Moberg

Ian B Hanson

Wayne A Morgan

Arnab Kumar Chatterjee

Gopikrishnan Soundararajan

David Choy

Bahar Reghabi

Sheng Ding

Xiao-dong Xiang

Laurent Meijer

Louis J Lintereur

Feng Wang

Eric Allan Larson

Rebecca K Gottlieb

Ying Wang

Raghavendhar Gautham

Fred Harrison Gage

Feng Tian

David B Ring

Tao Wei

Shifeng Pan

Yongqin Wan

Xing Wang

Chia-Hung Chiu

Stephen David Harrison

Hsiao-Yu S Kow

Mark A Gallop

Richard A Lerner

Yan Liu

David J Lockhart

Keith Hall

Martin Devenney

Daniel Mark Giaquinta

Richard J Schultz

Junko Tamiya

Qiang Ding

David Christopher Antonio

Ryan Aaron Mehl

Eric L Meggers

Stephen William Santoro

Miro Pastrnak

T Ashton Cropp

Lital Alfonta

Luke L Lairson

Weijun Shen

Pengyu Yang

Alexander Deiters

Raymond C Stevens

Earl Cornell

Robert A Nordmeyer

Yong Zhang

Derek T Yegian

Xiao-Dong Sun

Vaughn V Smider

Kristen Johnson

Nathanael S Gray

Jose J Ruelas

Joseph M Jaklevic

Bernard D Santarsiero

Jiangyun Wang

Jason Thomas Roland

Xiao-Dong Xiang

Shuibing C Chen

Sung-Hou Kim

John Tellew

Ashwin K Rao

Anil Gupta

Jie Wang

Costas A Lyssiotis

Joshua Payette

Michael P Cooke

Mohammad R Seyedsayamdost

Andrew Malcolm Bray

Hsifu Wang

Omar A Bazirgan

Jan Grunewald

Sarah R Hanson

Qing Lin

Wenshe Liu

Lisa Wodicka

Systems and methods are described herein for utilizing a photoacoustic sensor for estimating analyte concentration levels. Also described here are training methods for training an analyte sensor to more accurately estimate an analyte concentration level on the basis of a received acoustic signal.

Miniaturized noninvasive glucose sensor and continuous glucose monitoring system

The disclosed techniques involve a light emitter configured to emit light toward the skin of a person, a light emitter controller configured to control the light emitter to emit the light in pulses having a pulse duration and at a pulse repetition frequency, a resonance chamber positioned to receive acoustic waves generated in the person in response to the light emitted by the light emitter, a sensor configured to sense acoustic waves in the resonance chamber, and a signal processor configured to estimate a glucose concentration level in the person based on the acoustic waves sensed by the sensor. The resonance chamber is sized to form a standing wave that has an acoustic wavelength of interest when glucose analytes are present in the region of the skin of the person. The pulse duration and the pulse repetition frequency of the emitted light are set at values that support the standing wave having the acoustic wavelength of interest.

Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Long-acting dual GIP/GLP-1 peptide conjugates and methods of use

Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.

Relaxin immunoglobulin fusion proteins and methods of use

The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.

Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.

Humanized anti-CD3 antibodies, conjugates and uses thereof

A pump for delivering a fluid includes a pump housing that defines at least one reservoir having a circumferentially open first end, a circumferentially closed second end and a chamber to receive the fluid. The pump includes a plunger assembly having at least one plunger arm and a cannula fluidly coupled to the plunger arm to dispense the fluid from the pump. The plunger arm is receivable within the first end of the reservoir, and the at least one plunger arm defining an internal conduit to receive the fluid from the at least one fluid reservoir. The internal conduit is fluidly coupled to the cannula. The plunger assembly is movable in a first direction relative to the pump housing to advance the plunger arm within the fluid reservoir to dispense the fluid from the fluid reservoir out of the pump via the cannula.

Systems for wearable infusion port and associated pump

A blood glucose sensing system includes a sensor and a sensor electronics device. The sensor includes a plurality of electrodes. The sensor electronics device includes stabilization circuitry. The stabilization circuitry causes a first voltage to be applied to one of the electrodes for a first timeframe and causes a second voltage to be applied to one of the electrodes for a second timeframe. The stabilization circuitry repeats the application of the first voltage and the second voltage to continue the anodic—cathodic cycle. The sensor electronics device may include a power supply, a regulator, and a voltage application device, where the voltage application device receives a regulated voltage from the regulator, applies a first voltage to an electrode for the first timeframe, and applies a second voltage to an electrode for the second timeframe.

Method of and system for stabilization of sensors

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (I): as defined herein. Compounds for practice of a method of the invention can be delivered via oral delivery for systemic exposure, as well as delivered intratumorally. Antitumor therapy using a compound of formula (I) can further comprise administration of an effective dose of an immune-checkpoint targeting drug.

Agonists of stimulator of interferon genes sting

Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

Coiled coil immunoglobulin fusion proteins and compositions thereof

Growing community of inventors

Oakland, CA, United States of America

Peter G Schultz